{
    "clinical_study": {
        "@rank": "58625", 
        "arm_group": {
            "arm_group_label": "Treatment (palifosfamide)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive palifosfamide IV over 30 minutes on days 1-3. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies how well palifosfamide works in treating patients with recurrent\n      germ cell tumors. Drugs used in chemotherapy, such as palifosfamide, work in different ways\n      to stop the growth of tumor cells, either by killing the cells or by stopping them from\n      dividing"
        }, 
        "brief_title": "Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Adult Central Nervous System Germ Cell Tumor", 
            "Adult Teratoma", 
            "Malignant Extragonadal Germ Cell Tumor", 
            "Malignant Extragonadal Non-Seminomatous Germ Cell Tumor", 
            "Extragonadal Seminoma", 
            "Recurrent Malignant Testicular Germ Cell Tumor", 
            "Recurrent Ovarian Germ Cell Tumor", 
            "Stage IV Extragonadal Non-Seminomatous Germ Cell Tumor", 
            "Stage IV Extragonadal Seminoma", 
            "Stage IV Ovarian Germ Cell Tumor"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Seminoma", 
                "Teratoma", 
                "Testicular Neoplasms", 
                "Neoplasms, Germ Cell and Embryonal", 
                "Germinoma", 
                "Ovarian Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To determine the response rate (complete response [CR]+partial response [PR]) of single\n      agent palifosfamide in patients with refractory germ cell tumors.\n\n      SECONDARY OBJECTIVES:\n\n      I. To determine the duration of remission. II. To determine progression free and overall\n      survival. III. To assess toxicity and tolerability of palifosfamide in patients with germ\n      cell tumors.\n\n      OUTLINE:\n\n      Patients receive palifosfamide intravenously (IV) over 30 minutes on days 1-3. Treatment\n      repeats every 21 days for up to 6 courses in the absence of disease progression or\n      unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up every 3 months for 3 years,\n      every 6 months for 2 years, and then annually thereafter."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histological or serological proof of metastatic germ cell neoplasm\n             (gonadal or extragonadal primary) with disease not amenable to cure with either\n             surgery or chemotherapy; patients with seminoma and nonseminoma are eligible, as are\n             women with ovarian germ cell tumors\n\n          -  Patients must have evidence of recurrent or metastatic carcinoma by one or more of\n             the criteria specified in the protocol\n\n          -  Patients must have received initial cisplatin based combination therapy (such as\n             bleomycin, etoposide and cisplatin [BEP], etoposide and cisplatin [EP], VP-16 plus\n             ifosfamide plus cisplatin [VIP] or similar regimens) AND demonstrated progression\n             following the administration of at least one 'salvage' regimen for advanced germ cell\n             neoplasm (such as high dose chemotherapy, paclitaxel/ifosfamide/cisplatin [TIP] or\n             vinblastine, ifosfamide and cisplatin [VeIP])\n\n          -  Patients must have documented \"failure\" of prior therapy as defined in the protocol\n\n          -  Patients are eligible after first line platinum based chemotherapy if their disease\n             has relapsed and they have primary mediastinal non seminomatous germ cell tumor\n             (PMNSGCT) or late relapse (> 2 years) not amenable to surgical resection\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          -  Laboratory test results must be within ranges established in the protocol\n\n          -  Potential subject must have the ability to understand (as judged by the treating\n             physician) and willingness to provide written informed consent and Health Insurance\n             Portability and Accountability Act (HIPAA) authorization for release of personal\n             health information;\n\n          -  Females of childbearing potential must not be pregnant or breast-feeding; male and\n             female patients of reproductive potential must agree to use a highly reliable method\n             of birth control from the screening visit through 28 days after the last dose of\n             study drug\n\n        Exclusion Criteria:\n\n          -  No active clinically serious infections as judged by the treating investigator (>\n             CTCAE grade 2) including known human immunodeficiency virus (HIV) infection or\n             chronic active hepatitis B or active hepatitis C\n\n          -  No presence of, or history of any illness or injury to the urinary tract which may\n             make the patient more susceptible to acute renal insufficiency in the case of\n             potential renal adverse events\n\n          -  Patients must not have any cardiac disorders as defined in the protocol\n\n          -  No history of psychiatric illness/social situations that would limit compliance with\n             study requirements\n\n          -  Patients must be at least 4 weeks post major surgery or significant traumatic injury\n             at time of study registration\n\n          -  Patients must be at least 7 days post any minor surgical procedure, excluding\n             placement of a vascular access device at the time of study registration\n\n          -  Patients must not have a known sensitivity to any component of palifosfamide or its\n             known excipients\n\n          -  Patients with active central nervous system (CNS) metastases are excluded\n\n          -  Patients must not have previously been exposed to palifosfamide\n\n          -  Patients must have at least 3 weeks after previous radiotherapy or chemotherapy and\n             have recovered from all major toxicities (except alopecia or grade 1 or 2 neuropathy)\n             at the time of registration"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01808534", 
            "org_study_id": "IUCRO-0403", 
            "secondary_id": [
                "NCI-2013-00510", 
                "1301010501"
            ]
        }, 
        "intervention": {
            "arm_group_label": "Treatment (palifosfamide)", 
            "description": "Given IV", 
            "intervention_name": "palifosfamide", 
            "intervention_type": "Drug", 
            "other_name": [
                "IPM-lysine", 
                "isophosphoramide mustard-lysine", 
                "ZIO-201"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Ifosfamide", 
                "Isophosphamide mustard"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "contact": {
                    "email": "mjbrames@iupui.edu", 
                    "last_name": "M. Jackie Brames, RN", 
                    "phone": "317-944-7929"
                }, 
                "contact_backup": {
                    "email": "leinhorn@iupui.edu", 
                    "last_name": "Lawrence H. Einhorn, MD", 
                    "phone": "317-948-4312"
                }, 
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Lawrence H. Einhorn", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "david.vaughn@uphs.upenn.edu", 
                    "last_name": "David J. Vaughn", 
                    "phone": "215-349-8140"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Abramson Cancer Center of The University of Pennsylvania"
                }, 
                "investigator": {
                    "last_name": "David J. Vaughn", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "craig.nichols@vmmc.org", 
                    "last_name": "Craig R. Nichols", 
                    "phone": "206-223-6193"
                }, 
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98101"
                    }, 
                    "name": "Virginia Mason Medical Center"
                }, 
                "investigator": {
                    "last_name": "Craig R. Nichols", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Multicenter Single Arm Phase II Study of Single Agent Palifosfamide in Recurrent and Incurable Germ Cell Tumors", 
        "overall_contact": {
            "email": "mjbrames@iupui.edu", 
            "last_name": "M. Jackie Brames, RN", 
            "phone": "317-944-7929"
        }, 
        "overall_contact_backup": {
            "email": "leinhorn@iupui.edu", 
            "last_name": "Lawrence H Einhorn, MD", 
            "phone": "317-948-4312"
        }, 
        "overall_official": {
            "affiliation": "Indiana University School of Medicine", 
            "last_name": "Lawrence H Einhorn, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Summarized in the evaluable population by proportions with 90% confidence intervals.", 
            "measure": "Rate of response (CR+PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and/or serum tumor markers (alpha fetoprotein and beta-hCG)", 
            "safety_issue": "No", 
            "time_frame": "Up to 5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01808534"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Summarized in the evaluable population by proportions with 90% confidence intervals.", 
                "measure": "Rate of CR", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "Summarized in the evaluable population by proportions with 90% confidence intervals.", 
                "measure": "Rate of PR", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "Summarized by Kaplan-Meier methods including 90% confidence intervals for the median using method of Brookmeyer and Crowley.", 
                "measure": "Duration of remission (CR + PR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "Summarized by Kaplan-Meier methods including 90% confidence intervals for the median using method of Brookmeyer and Crowley.", 
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "description": "Summarized by Kaplan-Meier methods including 90% confidence intervals for the median using method of Brookmeyer and Crowley.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 years"
            }, 
            {
                "measure": "Continuous disease-free survival rate at 12 months post-treatment initiation", 
                "safety_issue": "No", 
                "time_frame": "At 12 months"
            }, 
            {
                "description": "Tolerability will be summarized by the appropriate statistics of safety measures, including grade 3/4 toxicity rates. Counts and proportions by toxicity will be presented with exact binomial 90% confidence intervals. Counts and proportions of overall toxicity by patient, defined as experience of at least 1 grade 3/4 toxicity, will be calculated with exact binomial 90% confidence intervals. Relation of toxicity to treatment regimen will be presented by counts and proportions.", 
                "measure": "Adverse event rates, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 5 years"
            }
        ], 
        "source": "Indiana University", 
        "sponsors": {
            "collaborator": {
                "agency": "Ziopharm", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Indiana University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}